Related Experiment Videos
[Experimental and clinical evaluation of cefpiramide in pediatrics]
Insights
Cefpiramide (CPM) demonstrates broad-spectrum antibacterial activity in pediatric patients. This new cephem antibiotic showed a high clinical efficacy rate of 91.9% with no observed side effects.
Area of Science:
- Pediatric infectious diseases
- Pharmacology
- Microbiology
Background:
- Cefpiramide (CPM) is a novel cephem antibiotic evaluated for pediatric applications.
- Understanding its pharmacokinetic and pharmacodynamic properties is crucial for effective therapeutic use.
Observation:
- CPM exhibited potent in vitro activity against key pediatric pathogens, including S. aureus and H. influenzae.
- Pharmacokinetic studies revealed favorable serum concentrations, a half-life of approximately 3 hours, and urinary excretion.
- Cerebrospinal fluid penetration was observed in meningitis patients, indicating potential for central nervous system infections.
Findings:
- CPM demonstrated significant clinical effectiveness, with an excellent or good response in 91.9% of pediatric patients with various infections.
- Bacteriological eradication rates reached 95.5% for targeted organisms.
- No adverse effects or laboratory abnormalities were reported during the study.
Implications:
- Cefpiramide presents a promising therapeutic option for pediatric bacterial infections due to its broad spectrum and favorable safety profile.
- Further research may explore its utility in specific pediatric infectious disease contexts.
- The drug's ability to penetrate CSF warrants consideration for CNS infections.
Abstract:
Fundamental and clinical studies of cefpiramide (CPM), a new cephem antibiotic, were carried out in the field of pediatrics. 80% MICs of CPM against S. aureus, S. pyogenes, H. influenzae, E. coli, K. pneumoniae and P. aeruginosa were 1.56, 0.05, 0.39, 6.25, 0.78 and 25 micrograms/ml, respectively. Serum concentration of CPM after intravenous injection at a dose of 20 mg/kg to 3 children was 103.7 +/- 9.1 micrograms/ml at 15 minutes and 13.4 +/- 5.0 micrograms/ml at 8 hours, with half-life of 3.11 +/- 0.83 hours. The excretion rate of CPM into urine was 16.40 +/- 7.31% within 8 hours. The transfer of CPM to cerebrospinal fluid was 0.1 approximately 0.2 micrograms/ml at 1 hour after intravenous injection at a dose of 20 mg/kg to patients with Aseptic meningitis, and 0.4 approximately 4.0 micrograms/ml at 1 hour approximately 3 hours 15 minutes after intravenous injection at a dose of 50 mg/kg to patients with purulent meningitis. Clinical effects of CPM on 37 patients with various infections were excellent in 28 cases, good in 6 cases, fair in 2 cases and poor in 1 case. The effective rate (excellent and good) was 91.9%. Bacteriologically, the eradication rate in 23 isolated organisms was 95.5%. No side effects and abnormalities of laboratory findings were noted. It was concluded that CPM has a broad spectrum antibacterial activity both in vitro and in vivo.